Earlier versions of a spending cuts package targeted PEPFAR, the popular global AIDS relief program. The White House agreed to spare the program to avoid defections, and the spending cuts passed the ...

Note that some links may require registration or subscription. A New York man who entered an MRI room while a scan was taking ...

An investigation by Democratic senators has raised concerns about conflicts of interest in telehealth companies' ties to ...

Two Republican senators and a broad bipartisan coalition of funders and nonprofits prevented a 600% increase in taxes levied ...

Two Republican senators and a broad coalition of funders made a big difference for private foundations during negotiations ...

Eli Lilly (NYSE: LLY) has been on fire over the past two years. The drugmaker has generated excellent financial results and delivered strong market performance -- so strong that detractors might ...

Eli Lilly (NYSE:LLY) has been in the spotlight recently with a 3.96% share price increase over the past month. The selection of RyboDyn Inc. to join Lilly Gateway Labs stands out among recent ...

The acquisition aligns with Eli Lilly’s broader diversification strategy beyond its core diabetes and obesity treatment portfolio.

Eli Lilly & Co. agreed to buy gene-editing biotech company Verve Therapeutics Inc. for $1.3 billion, the drugmaker’s latest investment in an experimental medicine that could fuel its long-term ...

Eli Lilly LLY 0.30% agreed to acquire Verve Therapeutics VERV -0.27% for about $1 billion upfront, adding a potential treatment for cardiovascular disease to its portfolio. Under the agreement ...

Eli Lilly will buy Boston-based Verve Therapeutics, Inc. in a billion dollar deal with plans to advance Verve's new line of experimental cardiac health drugs.

Image source: Getty Images. Weight-management leaders like Eli Lilly have been seeking a solution to this problem, and the healthcare specialist may have made an important step in that direction.